Dr. Steven Shak on the Results of the TAILORx Trial for Breast Cancer
Shak says the study examined the prospective outcomes of 1626 women and showed that at 5 years, less than 1% of women had a distant recurrence.
Steven Shak, MD, chief Scientific Officer, Oncotype Dx, discusses the good news for patients with breast cancer emerging from the NCI-sponsored Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, trial.
The goal of the trial was to examine the effects of chemotherapy in patients with breast cancer who had a midrange recurrent score from 12 to 25. The analysis includes additional single gene results from patients with recurrence scores less than 11 who received hormonal therapy alone.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
